GlassScriptPhysician profile
Luke A Lennox
NPI 1912324393
$2,295.84
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.65 · 2021: $17.09 · 2022: $652 · 2023: $712 · 2024: $529 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.86 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $424.67 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $151.82 | 2022-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $138.45 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.69 | 2023-2024 | Spevigo |
| Pfizer INC. | $114.66 | 2022-2024 | |
| Galderma Laboratories, L.P. | $48.43 | 2024-2025 | Aklief |
| Incyte Corporation | $46.17 | 2022 | |
| Janssen Biotech, INC. | $39.57 | 2023 | Remicade, Stelara, Simponi Aria |
| Dermavant Sciences, INC. | $37.26 | 2023-2024 | Vtama |
| Ucb, INC. | $32.35 | 2022-2023 | Cimzia |
| Regeneron Healthcare Solutions, INC. | $22.39 | 2022 | |
| Amgen INC. | $16.73 | 2025 | Otezla |
| Biofrontera INC. | $16.49 | 2022 | |
| Lilly USA, LLC | $15.30 | 2023 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Lennox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.